JQ-1 attenuates microglial activation and retinal pathology in experimental diabetic retinopathy with modulation of Pagr1a/JAK2/STAT3 signaling.
Findings support a BRD4-associated Pagr1a/JAK2/STAT3 regulatory mechanism in diabetic retinal inflammation and identify Pagr1a as a candidate therapeutic target for further investigation.